The Effect of Rifampicin on the Plasma and Intracellular Pharmacokinetics of Tenofovir Alafenamide Fumarate in Participants with HIV-associated Tuberculosis
When combined with rifampicin, ART containing standard-dose TAF resulted in higher TFV-DP concentrations than TDF-based ART in participants with HIV-associated tuberculosis, supporting its use with rifampicin-containing tuberculosis therapy.
Authors
- Michelle Moorhouse (ORCID: https://orcid.org/0000-0002-8410-3247)
- Rephaim Mpofu (ORCID: https://orcid.org/0000-0002-4732-5879)
- Marta Boffito (ORCID: https://orcid.org/0000-0002-2213-1103)
- Simiso Mandisa Sokhela (ORCID: https://orcid.org/0000-0002-2707-1533)
- François Venter (ORCID: https://orcid.org/0000-0002-4157-732X)
- Gary Maartens (ORCID: https://orcid.org/0000-0003-3080-6606)
- Lubbe Wiesner (ORCID: https://orcid.org/0000-0002-9070-8699)
- Peter L. Anderson (ORCID: https://orcid.org/0000-0002-1200-8494)
- Nomathemba Chandiwana (ORCID: https://orcid.org/0000-0001-7866-2651)
- Phumla Sinxadi (ORCID: https://orcid.org/0000-0002-1312-3523)
Institutions
- Desmond Tutu HIV Foundation (ZA)
- University of Cape Town (ZA)
- University of the Witwatersrand (ZA)
- Chelsea and Westminster Hospital NHS Foundation Trust (GB)
- PharmacoGenetics (China) (CN)
- Imperial College London (GB)
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1097/qai.0000000000003810
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00